Quick Answer
Orthofix Medical Inc. reported R&D Expense of $65.85 million for fiscal year 2025.
Orthofix Medical Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $65.85M | -10.6% |
| 2024 | $73.64M | -8.2% |
| 2023 | $80.23M | +63.5% |
| 2022 | $49.06M | -1.1% |
| 2021 | $49.62M | +27.1% |
| 2020 | $39.06M | +12.8% |
| 2019 | $34.64M | +4.3% |
| 2018 | $33.22M | +11.8% |
| 2017 | $29.70M | +3.1% |
| 2016 | $28.80M | +9.1% |
| 2015 | $26.39M | +5.6% |
| 2014 | $24.99M | -6.6% |
| 2013 | $26.77M | -6.3% |
| 2012 | $28.58M | +25.0% |
| 2011 | $22.86M | -18.2% |
| 2010 | $27.96M | -11.1% |
| 2009 | $31.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.77M | -14.6% | -7.3% |
| June 30, 2025 | $15.93M | -11.7% | -19.4% |
| March 31, 2025 | $19.77M | +1.4% | +14.3% |
| September 30, 2024 | $17.29M | -6.8% | -4.2% |
| June 30, 2024 | $18.05M | -7.1% | -7.4% |
| March 31, 2024 | $19.49M | -16.4% | +5.0% |
| September 30, 2023 | $18.56M | +55.4% | -4.5% |
| June 30, 2023 | $19.42M | +52.2% | -16.7% |
- Orthofix Medical Inc. showed a decrease of -10.6% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Orthofix Medical Inc.’s r&d expense has grown by 109.3% (from $31.46 million to $65.85 million).
- The most recent figure is from Orthofix Medical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: